Previous 10 | Next 10 |
In this video from Motley Fool Live recorded on Nov. 12, executives from Sorrento Therapeutics (NASDAQ: SRNE) talk about the company's second-generation therapeutic antibody. An investigational new drug (IND) application has been submitted to the Food and Drug Administration. ...
In this video from Motley Fool Live recorded on Nov. 12, Henry Ji, chairman, president, and CEO of Sorrento Therapeutics (NASDAQ: SRNE) , talks with host Brian Orelli about how better-designed neutralizing antibodies can still make an impact in the crowded COVID-19 treatment and...
In this video from Motley Fool Live recorded on Nov. 12, executives from Sorrento Therapeutics (NASDAQ: SRNE) discuss the company's therapeutic antibodies to treat COVID-19, the disease caused by the novel coronavirus. Mark Brunswick, senior vice president of regulatory affa...
In this video from Motley Fool Live recorded on Nov. 12, Sorrento Therapeutics ' (NASDAQ: SRNE) chairman, president, and CEO Henry Ji and senior vice president of regulatory affairs Mark Brunswick discuss the company's three COVID-19 tests. None of the tests have gained an Emerg...
In this video from Motley Fool Live recorded on Nov. 12, executives from Sorrento Therapeutics (NASDAQ: SRNE) talk about how the company's COVID-19 therapeutic antibodies -- STI-1499 and STI-2020 -- can coexist with the coronavirus vaccines. Since the recording, both Moder...
In this video from Motley Fool Live , which was recorded on Nov. 12, Henry Ji, chairman, president, and CEO of Sorrento Therapeutics (NASDAQ: SRNE) , talks about how the biotech got its start. The company's focus on antibodies has helped it pivot from a previous focus on de...
In its recent 13F filing, Coatue Management reported a significant growth in total fund portfolio value to $19.05B from $11.37B in the earlier quarter.Notable buys: Best Buy (BBY), Expedia (EXPE), American Eagle Outfitters (AEO), L Brands (LB) and Gap (GPS).Q3 portfolio activity included nume...
Palm Beach, FL – November 17, 2020 – The pandemic has wreaked havoc across the healthcare industry, and has led medical researchers to redirect all their might towards developing test kits and antidotes for coronavirus. The growth of the global covid-19 detection kits market r...
As the coronavirus vaccine race continues, investors are increasingly ditching less prominent drugmakers exhibiting slow progress and/or financial woes; Inovio Pharmaceuticals (NASDAQ: INO) and Sorrento Therapeutics (NASDAQ: SRNE) are down between 8% and 36%, respectively,...
Shares of Sorrento Therapeutics (NASDAQ: SRNE) were jumping 11.2% higher as of 11:09 a.m. EST on Wednesday. The nice gain came after the company announced that it's filing an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin an earl...
News, Short Squeeze, Breakout and More Instantly...
Sorrento Therapeutics Inc. Company Name:
SRNE Stock Symbol:
NASDAQ Market:
Sorrento Therapeutics Inc. Website:
What goes up usually comes down, and that's exactly what happened with Sorrento Therapeutics (NASDAQ: SRNE) today. Shares of Sorrento were crashing 30.4% as of 3:38 p.m. ET on Wednesday after soaring more than 60% on Tuesday. Sorrento's huge surge yesterday came after the company anno...
A California-based %Biotech company is turning heads Wednesday morning after it was announced that the U.S. Bankruptcy Court granted an interim approval of the company’s $75 million debtor-in-possession financing. While bankruptcy court can get a little messy, traders seem to b...